JPWO2020018547A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020018547A5 JPWO2020018547A5 JP2021502574A JP2021502574A JPWO2020018547A5 JP WO2020018547 A5 JPWO2020018547 A5 JP WO2020018547A5 JP 2021502574 A JP2021502574 A JP 2021502574A JP 2021502574 A JP2021502574 A JP 2021502574A JP WO2020018547 A5 JPWO2020018547 A5 JP WO2020018547A5
- Authority
- JP
- Japan
- Prior art keywords
- oxazepan
- carboxamide
- ethyl
- cyano
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 201000001474 proteinuria Diseases 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 229940109239 creatinine Drugs 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 239000012190 activator Substances 0.000 claims description 5
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 5
- 239000003018 immunosuppressive agent Substances 0.000 claims description 5
- FCRODBUNBQJNPU-SFTDATJTSA-N (2S)-N-[(1S)-1-cyano-2-[4-(4-cyanophenyl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C1=CC=C(C=C1)C#N)NC(=O)[C@H]1OCCCNC1 FCRODBUNBQJNPU-SFTDATJTSA-N 0.000 claims description 4
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 4
- -1 Oxazole-5-yl Chemical group 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- 230000001861 immunosuppressant effect Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 230000002485 urinary effect Effects 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- BQIZWZAQEICNDG-GMAHTHKFSA-N (2S)-N-[(1S)-1-cyano-2-[4-(1-methyl-2-oxoquinolin-7-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C1=CC=C2C=CC(N(C2=C1)C)=O)NC(=O)[C@H]1OCCCNC1 BQIZWZAQEICNDG-GMAHTHKFSA-N 0.000 claims description 2
- SABYNPLHFAPZQF-RXVVDRJESA-N (2S)-N-[(1S)-1-cyano-2-[4-(3,3-difluoro-1-methyl-2-oxoindol-6-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C1=CC=C2C(C(N(C2=C1)C)=O)(F)F)NC(=O)[C@H]1OCCCNC1 SABYNPLHFAPZQF-RXVVDRJESA-N 0.000 claims description 2
- HSWVIXGRFREZJG-PXNSSMCTSA-N (2S)-N-[(1S)-1-cyano-2-[4-(3,4-difluorophenyl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C1=CC(=C(C=C1)F)F)NC(=O)[C@H]1OCCCNC1 HSWVIXGRFREZJG-PXNSSMCTSA-N 0.000 claims description 2
- WCWJGAFMGPMBQG-FPOVZHCZSA-N (2S)-N-[(1S)-1-cyano-2-[4-(3,7-dimethyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=C(C2=C(N(C(O2)=O)C)C1)C)NC(=O)[C@H]1OCCCNC1 WCWJGAFMGPMBQG-FPOVZHCZSA-N 0.000 claims description 2
- HZZYFVOLMKQYKP-UGKGYDQZSA-N (2S)-N-[(1S)-1-cyano-2-[4-(3-ethyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)CC)C1)NC(=O)[C@H]1OCCCNC1 HZZYFVOLMKQYKP-UGKGYDQZSA-N 0.000 claims description 2
- ORHUZDNZRYZSJO-UNMCSNQZSA-N (2S)-N-[(1S)-1-cyano-2-[4-(3-ethyl-7-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=C(C2=C(N(C(O2)=O)CC)C1)C)NC(=O)[C@H]1OCCCNC1 ORHUZDNZRYZSJO-UNMCSNQZSA-N 0.000 claims description 2
- QCTYSVBOKIUUFU-UGKGYDQZSA-N (2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-1,2-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(C(=NO2)C)C1)NC(=O)[C@H]1OCCCNC1 QCTYSVBOKIUUFU-UGKGYDQZSA-N 0.000 claims description 2
- DRQDONWWFWYTII-ICSRJNTNSA-N (2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzothiazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(S2)=O)C)C1)NC(=O)[C@H]1OCCCNC1 DRQDONWWFWYTII-ICSRJNTNSA-N 0.000 claims description 2
- PYXGGJVWIVBQRO-PMACEKPBSA-N (2S)-N-[(1S)-1-cyano-2-[4-(4-fluorophenyl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C1=CC=C(C=C1)F)NC(=O)[C@H]1OCCCNC1 PYXGGJVWIVBQRO-PMACEKPBSA-N 0.000 claims description 2
- NSLGCWMFHWURGT-FPOVZHCZSA-N (2S)-N-[(1S)-1-cyano-2-[4-(4-methyl-3-oxo-1,4-benzothiazin-6-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(CS2)=O)C)C1)NC(=O)[C@H]1OCCCNC1 NSLGCWMFHWURGT-FPOVZHCZSA-N 0.000 claims description 2
- QKDQSHLZLZUQOA-UGKGYDQZSA-N (2S)-N-[(1S)-1-cyano-2-[4-(4-methyl-3-oxo-1,4-benzoxazin-6-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(CO2)=O)C)C1)NC(=O)[C@H]1OCCCNC1 QKDQSHLZLZUQOA-UGKGYDQZSA-N 0.000 claims description 2
- UBRDXNDHEGQOTI-FPOVZHCZSA-N (2S)-N-[(1S)-1-cyano-2-[4-(4-methylsulfonylphenyl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C1=CC=C(C=C1)S(=O)(=O)C)NC(=O)[C@H]1OCCCNC1 UBRDXNDHEGQOTI-FPOVZHCZSA-N 0.000 claims description 2
- AYKAKRZDQIFHMD-WMZOPIPTSA-N (2S)-N-[(1S)-1-cyano-2-[4-(5-cyanothiophen-2-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1SC(=CC1)C#N)NC(=O)[C@H]1OCCCNC1 AYKAKRZDQIFHMD-WMZOPIPTSA-N 0.000 claims description 2
- UZXVZQQAOVNOKG-PMACEKPBSA-N (2S)-N-[(1S)-1-cyano-2-[4-(6-cyanopyridin-3-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=NC(=CC1)C#N)NC(=O)[C@H]1OCCCNC1 UZXVZQQAOVNOKG-PMACEKPBSA-N 0.000 claims description 2
- IVHOZTBKWBUDMJ-PXNSSMCTSA-N (2S)-N-[(1S)-1-cyano-2-[4-(7-fluoro-3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=C(C2=C(N(C(O2)=O)C)C1)F)NC(=O)[C@H]1OCCCNC1 IVHOZTBKWBUDMJ-PXNSSMCTSA-N 0.000 claims description 2
- PVRGXPYTNXSTMU-PXNSSMCTSA-N (2S)-N-[(1S)-1-cyano-2-[4-[3-(2,2-difluoroethyl)-7-fluoro-2-oxo-1,3-benzoxazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=C(C2=C(N(C(O2)=O)CC(F)F)C1)F)NC(=O)[C@H]1OCCCNC1 PVRGXPYTNXSTMU-PXNSSMCTSA-N 0.000 claims description 2
- LRDOUIXCGZNESR-REWPJTCUSA-N (2S)-N-[(1S)-1-cyano-2-[4-[3-(2-hydroxy-2-methylpropyl)-2-oxo-1,3-benzoxazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)CC(C)(C)O)C1)NC(=O)[C@H]1OCCCNC1 LRDOUIXCGZNESR-REWPJTCUSA-N 0.000 claims description 2
- GRJJVLYWMJAVMA-UNMCSNQZSA-N (2S)-N-[(1S)-1-cyano-2-[4-[3-(2-methoxyethyl)-2-oxo-1,3-benzothiazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(S2)=O)CCOC)C1)NC(=O)[C@H]1OCCCNC1 GRJJVLYWMJAVMA-UNMCSNQZSA-N 0.000 claims description 2
- JUXOTDAODWSCQS-REWPJTCUSA-N (2S)-N-[(1S)-1-cyano-2-[4-[3-(2-methoxyethyl)-2-oxo-1,3-benzoxazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)CCOC)C1)NC(=O)[C@H]1OCCCNC1 JUXOTDAODWSCQS-REWPJTCUSA-N 0.000 claims description 2
- WJXGZWWSCFPECN-URXFXBBRSA-N (2S)-N-[(1S)-1-cyano-2-[4-[3-(cyclopropylmethyl)-2-oxo-1,3-benzoxazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)CC2CC2)C1)NC(=O)[C@H]1OCCCNC1 WJXGZWWSCFPECN-URXFXBBRSA-N 0.000 claims description 2
- KFOHIWSKADTAQW-OZXSUGGESA-N (2S)-N-[(1S)-1-cyano-2-[4-[3-(oxan-4-ylmethyl)-2-oxo-1,3-benzoxazol-5-yl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)CC2CCOCC2)C1)NC(=O)[C@H]1OCCCNC1 KFOHIWSKADTAQW-OZXSUGGESA-N 0.000 claims description 2
- USBDHHJQNTYSNJ-PMACEKPBSA-N (2S)-N-[(1S)-1-cyano-2-[4-[4-(trifluoromethyl)phenyl]phenyl]ethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)NC(=O)[C@H]1OCCCNC1 USBDHHJQNTYSNJ-PMACEKPBSA-N 0.000 claims description 2
- MUTKXUKCDAFWLB-ICSRJNTNSA-N (2S)-N-[(1S)-2-[4-(1,3-benzothiazol-5-yl)phenyl]-1-cyanoethyl]-1,4-oxazepane-2-carboxamide Chemical compound S1C=NC2=C1C=CC(=C2)C2=CC=C(C=C2)C[C@@H](C#N)NC(=O)[C@H]2OCCCNC2 MUTKXUKCDAFWLB-ICSRJNTNSA-N 0.000 claims description 2
- GCGGEFOSHQPZEX-PXNSSMCTSA-N (2S)-N-[(1S)-2-[4-(4-carbamoyl-3-fluorophenyl)phenyl]-1-cyanoethyl]-1,4-oxazepane-2-carboxamide Chemical compound C(N)(=O)C1=C(C=C(C=C1)C1=CC=C(C=C1)C[C@@H](C#N)NC(=O)[C@H]1OCCCNC1)F GCGGEFOSHQPZEX-PXNSSMCTSA-N 0.000 claims description 2
- KTGYWWMCWUTXTI-PXNSSMCTSA-N (2S)-N-[(1S)-2-[4-(7-chloro-3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]-1-cyanoethyl]-1,4-oxazepane-2-carboxamide Chemical compound ClC1=CC(=CC=2N(C(OC21)=O)C)C2=CC=C(C=C2)C[C@@H](C#N)NC(=O)[C@H]2OCCCNC2 KTGYWWMCWUTXTI-PXNSSMCTSA-N 0.000 claims description 2
- CBWWXOUBSQCMHB-GMAHTHKFSA-N (2S)-N-[(1S)-2-[4-[4-(azetidin-1-ylsulfonyl)phenyl]phenyl]-1-cyanoethyl]-1,4-oxazepane-2-carboxamide Chemical compound N1(CCC1)S(=O)(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C[C@@H](C#N)NC(=O)[C@H]1OCCCNC1 CBWWXOUBSQCMHB-GMAHTHKFSA-N 0.000 claims description 2
- YMWLPANQQFJYBL-UHFFFAOYSA-N (3-phenylphenyl)methanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC(C=2C=CC=CC=2)=C1 YMWLPANQQFJYBL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- AEXFXNFMSAAELR-RXVVDRJESA-N brensocatib Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)C)C1)NC(=O)[C@H]1OCCCNC1 AEXFXNFMSAAELR-RXVVDRJESA-N 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 238000009535 clinical urine test Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical group COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 description 36
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862699494P | 2018-07-17 | 2018-07-17 | |
| US62/699,494 | 2018-07-17 | ||
| PCT/US2019/042021 WO2020018547A1 (en) | 2018-07-17 | 2019-07-16 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530525A JP2021530525A (ja) | 2021-11-11 |
| JP2021530525A5 JP2021530525A5 (https=) | 2022-07-20 |
| JPWO2020018547A5 true JPWO2020018547A5 (https=) | 2022-07-20 |
Family
ID=69164738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502574A Pending JP2021530525A (ja) | 2018-07-17 | 2019-07-16 | ループス腎炎を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11998553B2 (https=) |
| EP (1) | EP3823627A4 (https=) |
| JP (1) | JP2021530525A (https=) |
| KR (1) | KR20210032431A (https=) |
| AU (1) | AU2019306532A1 (https=) |
| CA (1) | CA3106269A1 (https=) |
| WO (1) | WO2020018547A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (https=) | 2014-01-24 | 2018-02-24 | ||
| KR20250002710A (ko) | 2018-03-01 | 2025-01-07 | 아스트라제네카 에이비이 | (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물 |
| AU2019306532A1 (en) | 2018-07-17 | 2021-03-04 | Insmed Incorporated | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis |
| US20240150335A1 (en) * | 2021-02-05 | 2024-05-09 | Medshine Discovery Inc. | Fused ring derivatives containing 1,4-oxazepane |
| CN119156384B (zh) * | 2022-06-07 | 2025-12-09 | 瑞石生物医药有限公司 | 苯并[c]色满化合物的多晶型及其制备方法和用途 |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US6462076B2 (en) | 2000-06-14 | 2002-10-08 | Hoffmann-La Roche Inc. | Beta-amino acid nitrile derivatives as cathepsin K inhibitors |
| DE60131423T2 (de) | 2000-09-08 | 2009-03-19 | Prozymex A/S | Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| JP2005517640A (ja) | 2001-12-04 | 2005-06-16 | エフ．ホフマン−ラ ロシュ アーゲー | 置換２−アミノ−シクロアルカンカルボキサアミドならびにシステインプロテアーゼインヒビターとしてのその使用 |
| US20040253311A1 (en) | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
| WO2004076434A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
| US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
| ATE399763T1 (de) | 2003-05-30 | 2008-07-15 | Prozymex As | Proteasehemmer |
| JP2006527704A (ja) | 2003-06-18 | 2006-12-07 | プロザイメックス・アクティーゼルスカブ | プロテアーゼ阻害剤 |
| JP5301152B2 (ja) | 2004-04-07 | 2013-09-25 | ライナット ニューロサイエンス コーポレイション | 神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法 |
| EP2017620A3 (en) * | 2004-04-28 | 2009-04-22 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (DPP1) |
| US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
| GEP20094671B (en) | 2004-06-29 | 2009-04-27 | Nycomed Danmark Aps | Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention |
| CN103251953A (zh) | 2004-07-19 | 2013-08-21 | 约翰·霍普金斯大学 | 供免疫抑制的flt3抑制剂 |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| WO2007005668A2 (en) | 2005-06-30 | 2007-01-11 | Amgen Inc. | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer |
| AU2008223348A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| TW200916447A (en) | 2007-08-29 | 2009-04-16 | Methylgene Inc | Sirtuin inhibitors |
| BRPI0817311A2 (pt) | 2007-09-25 | 2015-03-17 | Novartis Ag | Tratamento de doenças pulmonares com medicamentos em aerossol tais como a vancomicina |
| WO2009074829A1 (en) | 2007-12-12 | 2009-06-18 | Astrazeneca Ab | Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| PE20100252A1 (es) | 2008-06-06 | 2010-04-12 | Boehringer Ingelheim Int | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina |
| CA2746220A1 (en) | 2008-12-08 | 2010-07-08 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
| RU2550133C2 (ru) | 2009-04-01 | 2015-05-10 | БИАЛ-ПОРТЕЛА энд КА., С.А. | Фармацевтические составы, включающие производные нитрокатехола, и способы их получения |
| CN102574830A (zh) | 2009-05-07 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | 取代的1-氰基乙基杂环基甲酰胺化合物750 |
| WO2010142985A1 (en) | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
| JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与 |
| WO2011154677A1 (en) | 2010-06-09 | 2011-12-15 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760 |
| WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
| US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| CA2863723C (en) | 2012-02-21 | 2020-09-22 | Carl Deutsch | 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors |
| ES2644965T3 (es) | 2012-04-17 | 2017-12-01 | Astellas Pharma Inc. | Compuesto heterocíclico aromático bicíclico nitrogenado |
| WO2014091443A1 (en) | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis |
| EP2775304A1 (en) | 2013-03-07 | 2014-09-10 | Universitätsspital Basel | Methods for detecting inflammatory disorder |
| JP6441831B2 (ja) | 2013-03-14 | 2018-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンｃの置換２−アザ−ビシクロ［２．２．２］オクタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 |
| PE20151727A1 (es) | 2013-03-14 | 2015-12-17 | Boehringer Ingelheim Int | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c |
| JP6437929B2 (ja) | 2013-03-14 | 2018-12-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 |
| US8871783B2 (en) | 2013-03-14 | 2014-10-28 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin C |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| JP6473738B2 (ja) | 2013-04-01 | 2019-02-20 | パルマトリックス，インコーポレイテッド | チオトロピウム乾燥粉末 |
| US10670594B2 (en) | 2013-08-22 | 2020-06-02 | Emory University | Devices and methods related to airway inflammation |
| WO2015032942A1 (en) | 2013-09-09 | 2015-03-12 | Prozymex A/S | N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors |
| WO2015032943A1 (en) | 2013-09-09 | 2015-03-12 | Prozymex A/S | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
| GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| NO2699580T3 (https=) | 2014-01-24 | 2018-02-24 | ||
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| MX2016013245A (es) | 2014-04-10 | 2017-01-16 | Novartis Ag | Regimen de dosificacion de liberacion inmediata de moduladores s1p. |
| SMT202000516T1 (it) | 2014-05-15 | 2020-11-10 | Insmed Inc | Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari |
| EP3149192B1 (en) | 2014-05-30 | 2019-01-02 | Versitech Limited | Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers |
| JP6529575B2 (ja) | 2014-08-01 | 2019-06-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用 |
| KR102510588B1 (ko) | 2014-09-12 | 2023-03-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 카텝신 c의 스피로사이클릭 억제제 |
| CA2965566A1 (en) | 2014-11-14 | 2016-05-19 | Boehringer Ingelheim International Gmbh | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists |
| DK3265452T3 (en) | 2015-03-05 | 2020-06-08 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
| KR20250107292A (ko) | 2016-07-29 | 2025-07-11 | 인스메드 인코포레이티드 | 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드 |
| AU2019217870A1 (en) | 2018-02-07 | 2020-08-27 | Insmed Incorporated | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides |
| KR20250002710A (ko) | 2018-03-01 | 2025-01-07 | 아스트라제네카 에이비이 | (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물 |
| AU2019306532A1 (en) | 2018-07-17 | 2021-03-04 | Insmed Incorporated | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis |
| US20210252015A1 (en) | 2018-07-17 | 2021-08-19 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease |
| WO2020214855A1 (en) | 2019-04-17 | 2020-10-22 | Azora Therapeutics, Inc. | Topical compositions and methods for treating inflammatory skin diseases |
| EA202193251A1 (ru) | 2019-06-05 | 2022-03-10 | Эмори Юниверсити | Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций |
| WO2022140516A1 (en) | 2020-12-22 | 2022-06-30 | Insmed Incorporated | Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease |
| CN112920124B (zh) | 2021-01-29 | 2024-03-01 | 安徽医科大学 | 一种嘧啶-2,4-二胺类化合物及其制备方法与应用 |
| WO2022232420A1 (en) | 2021-04-29 | 2022-11-03 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer |
| US20240226112A1 (en) | 2021-04-29 | 2024-07-11 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis |
| US20250049813A1 (en) | 2021-10-29 | 2025-02-13 | Insmed Incorporated | Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis |
| EP4479059A4 (en) | 2022-02-16 | 2026-01-28 | Insmed Inc | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVE |
-
2019
- 2019-07-16 AU AU2019306532A patent/AU2019306532A1/en not_active Abandoned
- 2019-07-16 US US17/260,606 patent/US11998553B2/en active Active
- 2019-07-16 WO PCT/US2019/042021 patent/WO2020018547A1/en not_active Ceased
- 2019-07-16 JP JP2021502574A patent/JP2021530525A/ja active Pending
- 2019-07-16 CA CA3106269A patent/CA3106269A1/en active Pending
- 2019-07-16 EP EP19837016.5A patent/EP3823627A4/en not_active Withdrawn
- 2019-07-16 KR KR1020217004073A patent/KR20210032431A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530525A5 (https=) | ||
| JP2021512904A5 (https=) | ||
| JP2023156479A5 (https=) | ||
| JP4854511B2 (ja) | 糖尿病治療剤 | |
| CN1155409C (zh) | 用于预防和治疗动脉硬化的药物组合物 | |
| JP2022096662A5 (https=) | ||
| RU2013138569A (ru) | Антагонисты рецептора минералокортикоидов | |
| JP5738871B2 (ja) | β３アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法 | |
| CN1158073C (zh) | 蛋白激酶c抑制剂在制备药物中的应用 | |
| JP2009526821A (ja) | 注意欠陥多動性障害治療用の新規な医薬組成物 | |
| BG64972B1 (bg) | Средство с антидепресивно действие | |
| RU2018144427A (ru) | Способы лечения ar+ рака молочной железы | |
| CN1431902A (zh) | 抗高血压剂与抗血管生成剂的治疗组合物 | |
| US20240366605A1 (en) | Use of quinazolinone compound for the treatment of cancer | |
| US20020107244A1 (en) | Combination treatment for depression | |
| CN1726028A (zh) | 固体口服剂型药物 | |
| JPWO2019157050A5 (https=) | ||
| JPWO2020018547A5 (https=) | ||
| WO2019151470A1 (ja) | 眼内血管新生及び／又は眼内血管透過性亢進を伴う眼科疾患の予防又は治療のための医薬 | |
| JPWO2020018551A5 (https=) | ||
| AU2003229724A1 (en) | Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency | |
| JP2810426B2 (ja) | 虚血治療用組成物 | |
| US20020147206A1 (en) | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | |
| JP5862897B2 (ja) | 腎機能障害の予防又は治療に用いる医薬 | |
| US20020198201A1 (en) | Combination of a PTPase inhibitor and an aldose reductase inhibitor |